The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection

Hospitalization for Lower Respiratory Tract Disease in Preterm Infants: Effects of Prophylaxis with Palivizumab

(2014) G. Faldella et al.   JOURNAL OF CHEMOTHERAPY

Respiratory syncytial virus infections in infants and children with congenital heart disease

(2013) Bernhard Resch et al.   CURRENT OPINION IN CARDIOLOGY

Immunology of bovine respiratory syncytial virus infection of cattle

(2012) Laurel J. Gershwin   COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES

Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States

(2012) Leonard B. Weiner et al.   JOURNAL OF MEDICAL ECONOMICS

Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis

(2011) Jessie R. Groothuis et al.   ADVANCES IN THERAPY

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children

(2011) Harish Nair et al.   BMC PUBLIC HEALTH

The multicenter Italian birth cohort study on incidence and determinants of lower respiratory tract infection hospitalization in infants at 33weeks GA or more: Preliminary results

(2011) Marcello Lanari et al.   EARLY HUMAN DEVELOPMENT

Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and/or Motavizumab

(2011) Qing Zhu et al.   JOURNAL OF INFECTIOUS DISEASES

Down Syndrome and Hospitalizations due to Respiratory Syncytial Virus: A Population-Based Study

(2011) Philip Zachariah et al.   JOURNAL OF PEDIATRICS

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria

(2011) Bernhard Resch et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season

(2010) Pilar Fernández et al.   BMC Pediatrics

The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children

(2010) Eric A.F. Simões et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Palivizumab prophylaxis in ‘late preterm’ newborns

(2010) Marcello Lanari et al.   Journal of Maternal-Fetal & Neonatal Medicine

Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

(2010) K. Huang et al.   JOURNAL OF VIROLOGY

Respiratory syncytial virus risk factors in late preterm infants

(2009) Marcello Lanari et al.   Journal of Maternal-Fetal & Neonatal Medicine

The Burden of Respiratory Syncytial Virus Infection in Young Children

(2009) Caroline Breese Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Severe respiratory syncytial virus (RSV) infection in infants with neuromuscular diseases and immune deficiency syndromes

(2009) Bernhard Resch et al.   Paediatric Respiratory Reviews

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Motavizumab, a Humanized, Enhanced-Potency Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus Infection in At-Risk Children

(2009) Katia Abarca et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Modified Recommendations for Use of Palivizumab for Prevention of Respiratory Syncytial Virus Infections

(2009)   PEDIATRICS

Clinical relevance of prevention of respiratory syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational age

(2008) X. Carbonell-Estrany et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES